LYMPHIR + Pembrolizumab Phase 1 Data Shows 24% ORR, 20.5-Month mPFS in Gynecologic Cancers
CTXR sits 33% above its 52-week low of $0.476.
Summary
Citius Pharmaceuticals' subsidiary presented detailed Phase 1 clinical trial data for LYMPHIR combined with pembrolizumab, showing a 24% Overall Response Rate (ORR) and a median Progression-Free Survival (mPFS) of 20.5 months in responders with recurrent or refractory gynecologic malignancies. This follows earlier general positive Phase 1 reports in March. For a small-cap biotech company that recently reported a net loss and a going concern warning, these specific positive efficacy numbers are crucial. The company is now planning a Phase 2 expansion in gynecologic cancers.
At the time of this announcement, CTXR was trading at $0.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.4M. The 52-week trading range was $0.48 to $2.48. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.